Below are the most recent publications written about "Anti-HIV Agents" by people in Profiles.
-
Maguire C, Rueve K, Farmer E, Huesgen E, Karaj A, Binkley A, Mounzer K, Brizzi M, Chary P, Sung P, Graziani A, Hiserodt E, Baron J, Koenig H, Short WR. Real World Virologic Outcomes in Patients With Elevated Body Mass Index Receiving Long Acting Cabotegravir/Rilpivirine. Clin Infect Dis. 2025 08 01; 81(1):67-74.
-
Atuhaire B, Muteebwa L, Nabunya R, Muhindo R, Ngabirano TD, Osingada CP, Muwanguzi PA. Brief Communication:?Factors associated with willingness to use long-acting injectable Cabotegravir for HIV pre-exposure prophylaxis (PrEP) among female undergraduate students at a Ugandan university. AIDS Res Ther. 2024 12 20; 21(1):95.
-
Short WR, Zimmerman MM, Mohamed O, Mofenson LM. Safety Data Timelines for Pregnant Individuals With HIV on Antiretroviral Therapy. Clin Infect Dis. 2024 12 17; 79(6):1472-1474.
-
Holt LM, Short WR, Momplaisir F, Hyun E, McKinney J, Lugo Morales A, Duque A, Druyan B, Ndubizu C, Duthely L, Joseph N, Sheth AN, Badell ML. Bictegravir Use During Pregnancy: A Multicenter Retrospective Analysis Evaluating HIV Viral Suppression and Perinatal Outcomes. Clin Infect Dis. 2024 11 22; 79(5):1258-1261.
-
Cluck DB, Chastain DB, Murray M, Durham SH, Chahine EB, Derrick C, Dumond JB, Hester EK, Jeter SB, Johnson MD, Kilcrease C, Kufel WD, Kwong J, Ladak AF, Patel N, P?rez SE, Poe JB, Bolch C, Thomas I, Asiago-Reddy E, Short WR. Consensus recommendations for the use of novel antiretrovirals in persons with HIV who are heavily treatment-experienced and/or have multidrug-resistant HIV-1: Endorsed by the American Academy of HIV Medicine, American College of Clinical Pharmacy. Pharmacotherapy. 2024 05; 44(5):360-382.
-
Cluck DB, Chastain DB, Murray M, Durham SH, Chahine EB, Derrick C, Dumond JB, Hester EK, Jeter SB, Johnson MD, Kilcrease C, Kufel WD, Kwong J, Ladak AF, Patel N, P?rez SE, Poe JB, Bolch C, Thomas I, Asiago-Reddy E, Short WR. Consensus recommendations for the use of novel antiretrovirals in persons with HIV who are heavily treatment-experienced and/or have multidrug-resistant HIV-1: Endorsed by the American Academy of HIV Medicine, American College of Clinical Pharmacy: An executive summary. Pharmacotherapy. 2024 05; 44(5):354-359.
-
Sonalkar S, McAllister A, Kete C, Fishman J, Frarey A, Short WR, Schreiber CA, Teitelman A. Implementation of an HIV Pre-exposure Prophylaxis Strategy Into Abortion and Early Pregnancy Loss Care. J Acquir Immune Defic Syndr. 2022 07 01; 90(S1):S129-S133.
-
Groves AK, Vadaketh J, Raziano VT, Nkwihoreze H, Short WR, Momplaisir F. Preexposure Prophylaxis Acceptability Among Pregnant Individuals and Implications for Human Immunodeficiency Virus Prevention. Obstet Gynecol. 2022 04 01; 139(4):537-544.
-
Sonalkar S, Short WR, McAllister A, Kete C, Ingeno L, Fishman J, Koenig HC, Schreiber CA, Teitelman AM. Incorporating HIV Pre-Exposure Prophylaxis Care for Patients Seeking Induced Abortion and Pregnancy Loss Management. Womens Health Issues. 2022 Jul-Aug; 32(4):388-394.
-
Orkin C, Squires KE, Molina JM, Sax PE, Sussmann O, Lin G, Kumar S, Hanna GJ, Hwang C, Martin E, Teppler H. Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (TDF) Versus Efavirenz/Emtricitabine/TDF in Treatment-naive Adults With Human Immunodeficiency Virus Type 1 Infection: Week 96 Results of the Randomized, Double-blind, Phase 3 DRIVE-AHEAD Noninferiority Trial. Clin Infect Dis. 2021 07 01; 73(1):33-42.